Annual EBIT
-$24.80 M
-$6.27 M-33.86%
December 31, 2023
Summary
- As of February 8, 2025, OCX annual earnings before interest & taxes is -$24.80 million, with the most recent change of -$6.27 million (-33.86%) on December 31, 2023.
- During the last 3 years, OCX annual EBIT has risen by +$6.13 million (+19.82%).
- OCX annual EBIT is now -609.67% below its all-time high of -$3.50 million, reached on December 31, 2013.
Performance
OCX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$13.46 M
-$8.94 M-197.70%
September 30, 2024
Summary
- As of February 8, 2025, OCX quarterly earnings before interest & taxes is -$13.46 million, with the most recent change of -$8.94 million (-197.70%) on September 30, 2024.
- Over the past year, OCX quarterly EBIT has dropped by -$6.99 million (-107.91%).
- OCX quarterly EBIT is now -325.49% below its all-time high of $5.97 million, reached on March 31, 2023.
Performance
OCX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$43.08 M
-$6.99 M-19.36%
September 30, 2024
Summary
- As of February 8, 2025, OCX TTM earnings before interest & taxes is -$43.08 million, with the most recent change of -$6.99 million (-19.36%) on September 30, 2024.
- Over the past year, OCX TTM EBIT has dropped by -$38.55 million (-851.14%).
- OCX TTM EBIT is now -2758.46% below its all-time high of -$1.51 million, reached on December 31, 2014.
Performance
OCX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
OCX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.9% | -107.9% | -851.1% |
| 3 y3 years | +19.8% | -71.3% | -7.0% |
| 5 y5 years | -63.2% | -71.3% | -7.0% |
OCX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -33.9% | +52.9% | -325.5% | +15.8% | -851.1% | +18.2% |
| 5 y | 5-year | -33.9% | +52.9% | -325.5% | +15.8% | -851.1% | +18.2% |
| alltime | all time | -609.7% | +52.9% | -325.5% | +15.8% | -2758.5% | +18.2% |
OncoCyte EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.46 M(+197.7%) | -$43.08 M(+19.4%) |
| Jun 2024 | - | -$4.52 M(-50.4%) | -$36.09 M(-9.5%) |
| Mar 2024 | - | -$9.11 M(-43.0%) | -$39.89 M(+60.8%) |
| Dec 2023 | -$24.80 M(+33.9%) | -$15.98 M(+146.8%) | -$24.80 M(+447.6%) |
| Sep 2023 | - | -$6.47 M(-22.2%) | -$4.53 M(-15.3%) |
| Jun 2023 | - | -$8.32 M(-239.3%) | -$5.34 M(+9.4%) |
| Mar 2023 | - | $5.97 M(+39.0%) | -$4.89 M(-65.7%) |
| Dec 2022 | -$18.53 M(-64.8%) | $4.29 M(-158.9%) | -$14.24 M(-57.9%) |
| Sep 2022 | - | -$7.29 M(-7.3%) | -$33.79 M(-16.0%) |
| Jun 2022 | - | -$7.86 M(+132.4%) | -$40.25 M(-9.8%) |
| Mar 2022 | - | -$3.38 M(-77.8%) | -$44.63 M(-15.3%) |
| Dec 2021 | -$52.66 M(+70.2%) | -$15.26 M(+11.0%) | -$52.66 M(+20.2%) |
| Sep 2021 | - | -$13.75 M(+12.4%) | -$43.79 M(+19.2%) |
| Jun 2021 | - | -$12.24 M(+7.2%) | -$36.75 M(+9.6%) |
| Mar 2021 | - | -$11.41 M(+78.6%) | -$33.54 M(+8.4%) |
| Dec 2020 | -$30.93 M(+39.1%) | -$6.39 M(-4.7%) | -$30.93 M(-3.5%) |
| Sep 2020 | - | -$6.71 M(-25.8%) | -$32.07 M(+4.7%) |
| Jun 2020 | - | -$9.03 M(+2.6%) | -$30.62 M(+13.2%) |
| Mar 2020 | - | -$8.80 M(+17.0%) | -$27.05 M(+22.5%) |
| Dec 2019 | -$22.24 M | -$7.52 M(+43.1%) | -$22.09 M(+18.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$5.26 M(-3.8%) | -$18.61 M(+13.6%) |
| Jun 2019 | - | -$5.46 M(+42.1%) | -$16.38 M(+8.2%) |
| Mar 2019 | - | -$3.85 M(-5.0%) | -$15.14 M(+0.8%) |
| Dec 2018 | -$15.20 M(-20.6%) | -$4.05 M(+33.9%) | -$15.01 M(+1.0%) |
| Sep 2018 | - | -$3.02 M(-28.5%) | -$14.86 M(-20.4%) |
| Jun 2018 | - | -$4.23 M(+13.7%) | -$18.67 M(+2.7%) |
| Mar 2018 | - | -$3.72 M(-4.5%) | -$18.18 M(-5.1%) |
| Dec 2017 | -$19.16 M(+72.0%) | -$3.89 M(-43.1%) | -$19.16 M(+4.3%) |
| Sep 2017 | - | -$6.83 M(+82.8%) | -$18.36 M(+30.2%) |
| Jun 2017 | - | -$3.74 M(-20.3%) | -$14.11 M(+9.4%) |
| Mar 2017 | - | -$4.69 M(+51.6%) | -$12.90 M(+15.8%) |
| Dec 2016 | -$11.14 M(+27.8%) | -$3.09 M(+19.8%) | -$11.14 M(-3.8%) |
| Sep 2016 | - | -$2.58 M(+2.0%) | -$11.58 M(+1.5%) |
| Jun 2016 | - | -$2.53 M(-13.6%) | -$11.41 M(+11.0%) |
| Mar 2016 | - | -$2.93 M(-17.1%) | -$10.28 M(+18.0%) |
| Dec 2015 | -$8.72 M(+74.9%) | -$3.54 M(+46.9%) | -$8.71 M(+30.3%) |
| Sep 2015 | - | -$2.41 M(+71.3%) | -$6.69 M(+56.3%) |
| Jun 2015 | - | -$1.41 M(+2.8%) | -$4.28 M(+48.9%) |
| Mar 2015 | - | -$1.37 M(-9.3%) | -$2.87 M(+90.7%) |
| Dec 2014 | -$4.98 M(+42.6%) | -$1.51 M | -$1.51 M |
| Dec 2013 | -$3.50 M | - | - |
FAQ
- What is OncoCyte annual earnings before interest & taxes?
- What is the all time high annual EBIT for OncoCyte?
- What is OncoCyte annual EBIT year-on-year change?
- What is OncoCyte quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for OncoCyte?
- What is OncoCyte quarterly EBIT year-on-year change?
- What is OncoCyte TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for OncoCyte?
- What is OncoCyte TTM EBIT year-on-year change?
What is OncoCyte annual earnings before interest & taxes?
The current annual EBIT of OCX is -$24.80 M
What is the all time high annual EBIT for OncoCyte?
OncoCyte all-time high annual earnings before interest & taxes is -$3.50 M
What is OncoCyte annual EBIT year-on-year change?
Over the past year, OCX annual earnings before interest & taxes has changed by -$6.27 M (-33.86%)
What is OncoCyte quarterly earnings before interest & taxes?
The current quarterly EBIT of OCX is -$13.46 M
What is the all time high quarterly EBIT for OncoCyte?
OncoCyte all-time high quarterly earnings before interest & taxes is $5.97 M
What is OncoCyte quarterly EBIT year-on-year change?
Over the past year, OCX quarterly earnings before interest & taxes has changed by -$6.99 M (-107.91%)
What is OncoCyte TTM earnings before interest & taxes?
The current TTM EBIT of OCX is -$43.08 M
What is the all time high TTM EBIT for OncoCyte?
OncoCyte all-time high TTM earnings before interest & taxes is -$1.51 M
What is OncoCyte TTM EBIT year-on-year change?
Over the past year, OCX TTM earnings before interest & taxes has changed by -$38.55 M (-851.14%)